NDA 022173 · Cheplapharm
Zyprexa Relprevv
Olanzapine Pamoate · Intramuscular
Last checked: Nov 20, 2026Latest source record: May 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Dec 11, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
495
150 Phase 3, 32 recruiting
FAERS reports
40,828
31,555 serious, 4,498 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POST-INJECTION DELIRIUM/SEDATION SYNDROME and INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS WARNING: POST-INJECTION DELIRIUM/SEDATION SYNDROME and INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Patients are at risk for severe sedation (including coma) and/or delirium after each injection and must be observed for at least 3 hours in a certified healthcare setting with ready access to emergency response services. Because of this risk, ZYPREXA RELPREVV is available only through a restricted distribution program called ZYPREXA RELPREVV REMS and requires prescriber, healthcare setting, patient, and pharmacy enrollment. ( 2.1 , 5.1 , 5.2 , 10.2 , 17 ) Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ZYPREXA...
What it is approved for
From the label in effect May 19, 2026.
ZYPREXA RELPREVV is available only through a restricted distribution program [see Warnings and Precautions ( 5.2 )] . ZYPREXA RELPREVV must not be dispensed directly to a patient. For a patient to receive treatment, the prescriber, healthcare setting, patient, and pharmacy must all be enrolled in the ZYPREXA RELPREVV REMS. To enroll, call 1-877-772-9390. ZYPREXA ® RELPREVV™ is a long-acting atypical antipsychotic for intramuscular injection indicated for the treatment of schizophrenia. ( 1.1 ) Efficacy was established in two clinical trials in patients with schizophrenia: one 8-week trial in adults and one maintenance trial in adults. ( 14.1 ) 1.1 Schizophrenia ZYPREXA RELPREVV is indicated for the treatment of schizophrenia. Efficacy was established in two clinical trials in patients with schizophrenia: one 8-week trial in adults and one maintenance trial in adults [see Clinical Studies ( 14.1 )] .
Mechanism: The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 11, 2009 Original approval · Type 3 - New Dosage Form Other Important Information from FDASummary ReviewLabel
3 products under this application
- ZYPREXA RELPREVV · OLANZAPINE PAMOATE EQ 405MG BASE/VIAL · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- ZYPREXA RELPREVV · OLANZAPINE PAMOATE EQ 210MG BASE/VIAL · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- ZYPREXA RELPREVV · OLANZAPINE PAMOATE EQ 300MG BASE/VIAL · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olanzapine Pamoate" as an intervention, any sponsor and status, largest first.
- Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00418171 · 18,239 participants · Start Feb 2002
Drug: Ziprasidone; Olanzapine · For: Schizophrenia
Sites: San Bernardino, California; ‘Aiea, Hawaii; Schaumburg, Illinois · 5 sites in all
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknown
Tianjin Medical University General HospitalAcademic, hospital or other
NCT03790085 · 2,700 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Risperidone; Olanzapine and 1 more · For: Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Sites: Tianjin, China
- Metabolic Profile and Anthropometric Changes in SchizophreniaPivotal-lookingCompleted
Central Institute of Psychiatry, Ranchi, IndiaAcademic, hospital or other
NCT00534183 · 2,006 participants · Start Jun 2006
Drug: Olanzapine; Risperidone and 1 more · For: Metabolic Syndrome; Diabetes; Obesity
Sites: Ranchi, India
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
- Treatment of Refractory Nausea and Vomiting in Patients With Breast CancerPivotal-lookingCompleted
University of Rochester NCORP Research BaseAcademic, hospital or other
NCT03367572 · 1,363 participants · Start Apr 19, 2018 · Primary completion Apr 13, 2024
Drug: Dexamethasone; Netupitant/Palonosetron Hydrochloride and 2 more · For: Breast Carcinoma
Sites: Honolulu, Hawaii; Decatur, Illinois; New Orleans, Louisiana · 18 sites in all
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00212784 · 1,225 participants · Start Sep 4, 2003 · Primary completion Mar 15, 2006
Drug: asenapine; olanzapine · For: Schizophrenia; Schizoaffective Disorder
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diabetes mellitus4,878
- weight increased4,144
- drug ineffective1,953
- off label use1,900
- pancreatitis1,734
- hypertension1,688
- type 2 diabetes mellitus1,639
- anxiety1,571
- nausea1,466
- somnolence1,410
- fatigue1,388
- insomnia1,351
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,651 |
| 2005 | 2,497 |
| 2006 | 3,074 |
| 2007 | 2,993 |
| 2008 | 1,331 |
| 2009 | 2,936 |
| 2010 | 2,552 |
| 2011 | 2,496 |
| 2012 | 1,837 |
| 2013 | 1,224 |
| 2014 | 1,275 |
| 2015 | 5,915 |
| 2016 | 1,368 |
| 2017 | 1,532 |
| 2018 | 1,381 |
| 2019 | 1,372 |
| 2020 | 1,176 |
| 2021 | 936 |
| 2022 | 960 |
| 2023 | 790 |
| 2024 | 580 |
| 2025 | 583 |
| 2026 | 368 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zyprexa Relprevv (Olanzapine Pamoate)
2024 spending
$1.4M
Beneficiaries
252
1,394 claims
Per beneficiary
$5,699
$911.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,449,379 |
| 2021 | $5,246,409 |
| 2022 | $4,806,762 |
| 2023 | $4,070,202 |
| 2024 | $1,436,272 |
Part B: Zyprexa Relprevv (Olanzapine Pamoate) · HCPCS J2358
2024 spending
$64K
Beneficiaries
338
406 claims
Per beneficiary
$190
2024 ASP limit $2.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $51,476 |
| 2021 | $184,574 |
| 2022 | $231,116 |
| 2023 | $0 |
| 2024 | $64,067 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review.
Baeza I, Fortea A, Ilzarbe D, et al. · Paediatr Drugs 2023 · Systematic Review
- Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications.
Uchida H, Suzuki T · J Clin Psychopharmacol 2014 · Systematic Review
- Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.
Keramatian K, Chakrabarty T, Yatham LN · CNS Drugs 2019 · Systematic Review
- Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
Gentile S · Pharmacotherapy 2013 · Systematic Review
- Second-generation antipsychotic long-acting injections: systematic review.
Fleischhacker WW · Br J Psychiatry Suppl 2009 · Systematic Review
- D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.
Mamo D, Kapur S, Keshavan M, et al. · Neuropsychopharmacology 2008 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Cheplapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.